(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Physiomics PLC on Wednesday said its personalised dosing software project has now obtained the key approvals needed to progress with its observational trial. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Physiomics PLC on Tuesday said that it has been awarded a new contract by an existing, large pharmaceutical client. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Wins new contract from "an existing, large client", worth GBP186,000. According to the agreement, the client will use Physiomics' proprietary Virtual Tumour platform to model its targeted oncology agents in combination with other modalities, in order to help inform dose and scheduling decisions. As a result, Physiomics will be entering the next financial year - ending June 30, 2025 - with committed revenue of over GBP500,000. Read More
Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Says it has been awarded a significant contract by a new UK-based biotech client, which it left unnamed. "This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas," the company says. The project involves the use of Physiomics' Virtual Tumour technology to help guide the phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at GBP161,580 and is anticipated to be completed over the next five months. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and Friday this week and not separately reported by Alliance News: Read More
Physiomics PLC - Milton Park, England-based data science company, focused on new therapeutics and personalised medicine solutions - Warns several large contracts have taken longer than expected to be signed. It predicts total income for the year to June 30 will decline to a range of GBP600,000-GBP650,000 as a result. It adds: "The company is in the final stages of negotiation for two projects (one with an existing client and one with a potential new client), the total value of which is expected to be, in aggregate, approximately GBP350,000. Whilst the board anticipates that the contracts for these two projects will be signed in FY24, the majority of the revenue is now expected be recognised in the company's next financial year ending 30 June 2025, and accordingly the board's expectations for FY25 revenues have been correspondingly increased." Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a "substantial" new contract by an existing "large pharma" client, though doesn't specify whom the client is. The project, which is valued at GBP178,000, involves involves pharmacokinetic-pharmacodynamic modelling in the field of DNA damage and repair fields. It is designed to help inform clinical dose and scheduling decisions. Physiomics expects this work to be completed over the course of the next six months. Read More
(Alliance News) - Physiomics PLC on Thursday reported higher interim revenue and a narrowed loss. Read More
(Alliance News) - Physiomics PLC on Monday said that it has been awarded a contract by the University of Sheffield to support a grant-funded project focused on an insect model of cancer treatment. Read More
Physiomics PLC - mathematical modelling company that supports oncology drug development - Wins further contract from existing client Numab Therapeutics AG. Says the project involves pharmacokinetic-pharmacodynamic modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions. Chief Executive Officer Peter Sargent comments: "We are thrilled to have this opportunity to continue working with and supporting Numab on this asset through its preclinical stages as it heads into the clinic. Along with the project we announced with them in August 2023, this new project is testament to the continued support we provide and the great relationships we've built." Read More